14.5 Menopause, Vulvovaginal Symptoms, and Vaginal Discharge

Key Takeaways

  • Use the clinical pattern to identify typical perimenopause or menopause. Consider other causes and younger-age assessment where indicated.

  • Local therapy can address isolated genitourinary symptoms. Protect the endometrium when prescribing systemic oestrogen to a person with a uterus.

  • Differentiate BV, candidiasis and trichomoniasis using symptoms, examination findings and targeted testing. Use Irish treatment and partner pathways.

Last updated: November 2026

Recognise perimenopause and genitourinary symptoms

Perimenopause can present with a change in menstrual pattern and new hot flushes or night sweats. Ask about sleep, mood, effect on daily life, medications, menstrual and reproductive history and whether pregnancy is possible. In an otherwise healthy person aged over 45 with a typical history, diagnose clinically. Natural menopause is identified after 12 months without a period when the amenorrhoea can be attributed to menopause, such as in someone who is not taking hormonal contraception. Interpret symptoms with care after hysterectomy or when hormonal treatment alters the bleeding pattern. Seek other causes when the pattern is atypical. In those aged 40–45 with uncertainty, consider biochemical assessment. In those under 40 with menstrual disturbance, vasomotor symptoms or subfertility, investigate possible premature ovarian insufficiency and discuss its fertility, bone and health implications.

Lower oestrogen can thin the vulvovaginal epithelium and contribute to dryness, burning, dyspareunia and urinary symptoms. Genitourinary syndrome of menopause may include atrophic vaginitis and can coexist with infection, a dermatosis or prolapse. Ask about the character of discharge, visible blood, irritants, itch, pain, sexual history and urinary symptoms. Examine with consent when indicated. Thin or fragile tissue supports atrophy in the appropriate setting. Focal lesions, unexplained bleeding and persistent symptoms require evaluation for other causes. Use the Irish postmenopausal bleeding pathway when applicable.

Ask about distress and causes of low sexual desire

With permission and in private, distinguish reduced desire from pain, arousal or orgasm difficulties and ask whether the change is distressing to the patient. If it is, ask about the timing, mood, medicines, fatigue, pregnancy or lactation where relevant, relationship factors and personal safety. A patient who noticed reduced desire after starting an SSRI may need a medication and mood review. Another may avoid sex because penetration is painful and need a focused pain assessment and treatment. Lack of distress can call for reassurance even if a partner has different expectations. Tailor treatment to identified contributors and offer further psychosexual or specialist assessment where needed. International Consultation on Sexual Medicine recommendations.

Choose local or systemic treatment

For troublesome dryness or dyspareunia, discuss vaginal moisturisers and lubricants and, where suitable, low-dose vaginal oestrogen. Local therapy can be suitable for isolated genitourinary symptoms and can be added for persistent local symptoms despite systemic treatment. With previous breast cancer, start with non-hormonal options and review persistent symptoms with the treating team, especially with aromatase inhibitor use. Check the individual product information.

For bothersome vasomotor symptoms, discuss benefits, risks and personal preferences around systemic menopausal hormone therapy. Provide endometrial protection with an appropriate progestogen when the uterus is present. Oestrogen-only therapy is generally suitable after total hysterectomy if there is no other reason to add progestogen. Consider the route, thromboembolic and cardiovascular history, breast cancer history and other contraindications. With previous VTE, seek individual assessment and specialist advice before considering systemic treatment. If treatment is justified, the European guideline favours low-dose transdermal oestrogen. It advises against systemic therapy in people with previous breast cancer. Discuss non-hormonal approaches when suitable. Review efficacy and adverse effects after starting, around three months under the European Society of Endocrinology guideline, and reassess periodically. Systemic menopausal hormone therapy does not provide contraception.

Worked decision. A 55-year-old has isolated vaginal dryness and pain with penetration. She has no unexplained bleeding, concerning finding or breast cancer history. Discuss local treatment and symptom review. If she instead has new postmenopausal bleeding, evaluate the bleeding through the appropriate Irish pathway, even if dryness and atrophic findings coexist.

Sources: HSE menopause treatment · HSE types of HRT · European Society of Endocrinology 2025.

Distinguish the causes of vaginal discharge

Normal discharge varies with the cycle. New unpleasant odour, itch, bleeding, pelvic pain, urinary symptoms or pregnancy change the approach. Ask about duration, associated signs, sexual contact, medicines and self-treatment. Offer an appropriate examination and tests. Consider cervicitis and arrange exposure- and site-appropriate STI testing. Pelvic pain with cervical motion or adnexal tenderness warrants assessment for pelvic inflammatory disease. Pain or bleeding in someone who could be pregnant requires pregnancy assessment. Fever or systemic illness raises urgency. Do not infer the organism from discharge colour alone.

PatternFindings that change the working diagnosisIrish community management
Bacterial vaginosisThin grey-white discharge, fishy odour and pH above 4.5. Vulval inflammation is often absent. Clinical findings matter because a swab showing associated organisms alone does not diagnose symptomatic BV.For appropriate symptomatic cases the HSE lists oral metronidazole 400 mg every 12 hours for 5–7 days or intravaginal clindamycin 2% for seven nights. Review pregnancy, interactions and formulation-specific advice. Recurrent symptoms warrant reassessment.
Vulvovaginal candidiasisItch, soreness, vulval erythema or fissuring, and sometimes thick white discharge. A low vaginal pH fits the diagnosis. Candida isolated without symptoms usually represents colonisation.A first typical uncomplicated presentation can be treated without a swab, for example with a clotrimazole pessary. Check the specific regimen in pregnancy and avoid oral azoles. If symptoms persist or recur, reassess for alternatives and obtain a swab where indicated before repeated treatment.
TrichomoniasisMay cause yellow-green frothy discharge, irritation and raised pH. A strawberry cervix is possible. Request a specific test for Trichomonas, such as PCR on a vulvovaginal swab, using local laboratory instructions.HSE first choice is metronidazole 400 mg every 12 hours for seven days. Offer other STI testing and arrange testing and treatment of partners from the four weeks before presentation. Advise avoiding sex for at least a week and until treatment and follow-up are completed for the patient and partner.
Genitourinary syndrome of menopause or irritationHistory of hypo-oestrogenism or topical irritant exposure, dryness and burning, thin tissue or another examination finding. Consider coexistence with infection or a skin disorder.Address irritants and review local menopause treatment where appropriate. Investigate unexpected bleeding or suspicious lesions.

A raised pH can support either BV or trichomoniasis; the history, examination and targeted test establish the distinction. The HSE recommends a trichomoniasis test of cure if the patient remains symptomatic or was asymptomatic when tested, optimally four weeks after starting treatment. Consider adherence or reinfection when symptoms persist. Trichomoniasis is notifiable. Follow HSE notification guidance and check whether the laboratory has already initiated notification. A frothy discharge with pelvic pain and fever also needs assessment for other causes and possible upper tract infection.

Sources: HSE STI consultation · HSE BV guideline · HSE candidiasis guideline · HSE trichomoniasis guideline.

Test Your Knowledge

A 54-year-old with an intact uterus reports frequent disruptive hot flushes and night sweats. Her last natural period was 18 months ago. She has no unexplained bleeding or contraindication to systemic therapy. She chooses systemic oestrogen after discussion. What additional treatment is normally needed?

A

Vaginal oestrogen for endometrial protection

B

An appropriate progestogen for endometrial protection

C

A combined contraceptive as a mandatory add-on

D

An antibiotic to prevent genitourinary symptoms

Test Your Knowledge

A 27-year-old has irritating frothy discharge and a positive vaginal nucleic acid test for Trichomonas vaginalis. She is not pregnant and has no pelvic pain or fever. Which plan best follows the HSE first-choice community pathway?

A

Repeat testing in six months and defer treatment

B

Treat with a topical antifungal and review in a week

C

Treat with oral metronidazole for seven days, offer other STI tests and arrange partner assessment and treatment

D

Treat with intravaginal clindamycin alone

Sections you finish are checked off in the contents.